Acute Kidney Injury clinical trials at UC Davis
1 research study open to eligible people
open to eligible people ages 18-85
Phase 3 multicenter study to be conducted in up to 90 qualified participating sites globally to assess the efficacy and safety of Reltecimod vs placebo in patients with sepsis-associated Stage 2/3 AKI.
Sacramento, California and other locations